What kind of medicine is Copanlisib?

Copanlisib is a drug used to treat a specific type of lymphoma. It belongs to a class of drugs called PI3K inhibitors. PI3K is the abbreviation of phosphatidylinositol 3 kinase, which is a protein enzyme involved in processes such as cell growth, differentiation and survival. PI3K is overactive in some cancers, especially B cell lymphomas such as follicular lymphoma (Follicular Lymphoma) and transformed lymphoma (Transformed Lymphoma).

Copanliside can prevent the growth and division of cancer cells by inhibiting the activity of thePI3K pathway, thereby slowing or stopping the progression of tumors. It is a targeted therapy with relatively high selectivity, mainly acting on malignant BB cells.

Copanliside is usually given as an intravenous injection, usually every three weeks. The treatment process requires the supervision of a medical professional as it may cause some adverse reactions such as high blood sugar, high blood pressure, increased risk of infection, etc.

In clinical trials, copanliside has shown effectiveness in certain lymphoma types, particularly those that are insensitive or resistant to other treatments. However, it does not work for all types of cancer and may cause some side effects, so treatment options should be discussed with the patient and doctor.

In summary, copanliside is a targeted drug used to treat certain types of lymphoma. It interferes with the growth and division of cancer cells by inhibiting thePI3K pathway, providing a treatment option for some patients. However, you should fully understand its potential risks and benefits before use, and conduct treatment under the guidance of a doctor.

Copanliside has just been launched in China and has not yet been included in medical insurance. The specific price may not be determined yet. Please consult your local pharmacy for details. There is only the American version of the original drug available abroad, and the price is as high as more than 70,000 yuan.